A detailed history of Comerica Bank transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Comerica Bank holds 519 shares of KALV stock, worth $6,913. This represents 0.0% of its overall portfolio holdings.

Number of Shares
519
Previous 711 27.0%
Holding current value
$6,913
Previous $8,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

SELL
$11.56 - $16.01 $2,219 - $3,073
-192 Reduced 27.0%
519 $6,000
Q1 2025

May 14, 2025

BUY
$7.4 - $12.6 $1,420 - $2,419
192 Added 36.99%
711 $8,000
Q4 2024

Feb 14, 2025

SELL
$8.09 - $12.5 $1,075 - $1,662
-133 Reduced 20.4%
519 $4,000
Q2 2024

Aug 15, 2024

BUY
$10.35 - $12.49 $1,376 - $1,661
133 Added 25.63%
652 $7,000
Q4 2023

Feb 14, 2024

SELL
$7.58 - $12.25 $204 - $330
-27 Reduced 4.95%
519 $6,000
Q3 2023

Nov 21, 2023

BUY
$8.95 - $11.35 $4,886 - $6,197
546 New
546 $5,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $328M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Comerica Bank Portfolio

Follow Comerica Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.